Introduction
============

According to recent studies, lung cancer is still the leading cause of cancer mortality both in males and females, which accounts for 18.4% of total cancer death [@B1]. A majority of lung cancer patients, approximately 85%, are diagnosed with non-small cell lung cancer (NSCLC) [@B2]. To the best of our knowledge, tobacco smoking is the main risk factor for lung cancer, and other factors are environmental- and occupational-related. Though the incidence rate has slightly decreased in recent years, the 5-year survival of lung cancer is merely 19% [@B3]. Most of the patients have been diagnosed with an advanced stage, the prognosis for patients with lung cancer is still depressing. Obviously, the prognosis of lung cancer patients with different stage varies greatly, it is necessary to improve survival by finding biomarkers for prognosis prediction. In addition to traditional prognostic factors including tumor microenvironment state and clinical stage, diverse outcomes of cancer patients may also attribute to genetic alterations [@B4].

In spite of other treatments, like surgery, targeted therapy, radiation, and immunity therapy, platinum-based chemotherapy is still the first-line treatment for lung cancer patients [@B5]. Platinum-based chemotherapy drugs mainly function by forming DNA adducts intrastrand and interstrand, cells recognize the adducts as DNA damage then activate DNA repair mechanisms, like nucleotide excision repair, mismatch repair, base-excision repair, non-homologous end-joining, and homologous recombination [@B6], [@B7]. The initial response of platinum in most lung cancer patients is generally good, but intrinsic or acquired resistance would influence the sensitivity of platinum. The underlying mechanisms are described as following: increased damage, decreased accumulation, detoxification, epigenetic changes, decreased apoptosis, membrane trafficking changes, and genetic variants [@B8]-[@B10].

Platinum resistance-related genes affect the efficacy of platinum-based chemotherapy, which may act on the prognosis of patients. There are many genes associated with platinum resistance, according to database searching and literature references, we chose *HMGB1*, *REV3L*, and *NFE2L2* to study the association between genetic variations and clinical outcome. *HMGB1* (high mobility group box 1) is situated in the nucleus to maintain nuclear homeostasis, which plays an indispensable role in many diseases and cellular processes, like tumor, inflammation, cell differentiation, and migration [@B11]. *HMGB1* directly binds to lesions of DNA then pursuits to DNA repair and tends to relate with platinum toxicity and liver damage [@B12], [@B13]. There are many reports about variants of *HMGB1*. The rs1045411 is related to the overall survival of gastric cancer and the risk of developing lung cancer, hepatocellular carcinoma, and lymph node metastasis of breast cancer [@B14]-[@B17]. The rs1412125 and rs2249825 appear to be significantly related to the risk of lung cancer and platinum response and seem to relate with the progression of breast cancer [@B15], [@B17]-[@B19]. *REV3L* (the zeta catalytic subunit of DNA polymerase) is the most important DNA polymerase, it plays a role in maintaining genome stability in the advent of DNA damage and cell proliferation after damage, also may inhibit tumorigenesis [@B20], [@B21]. Inhibition of *REV3L* sensitizes lung cancer and gliomas to cisplatin chemotherapy [@B22], [@B23]. The rs462779 and rs465646 in *REV3L* are associated with overall survival in platinum-treated malignant mesothelioma, rs462779 is also correlated with event-free survival and risk of colorectal cancer [@B24], [@B25]. Transcription factor *NFE2L2* (nuclear factor, erythroid 2 like 2), also named *NRF2*, functions as an oncogene or tumor suppressor, it regulates the cellular antioxidant response and promotes cancer chemotherapy resistance, metastasis, and progression [@B26]-[@B28]. The rs6706649 and rs6721961 in *NFE2L2* may influence breast cancer prognosis, rs6721961 and rs35652124 are associated with susceptibility to colorectal cancer [@B29], [@B30].

In this study, we investigate the associations of *HMGB1* (rs1045411, rs1412125, and rs2249825), *REV3L* (rs462779 and rs465646) and *NFE2L2* (rs6706649, rs6721961, and rs35652124) with platinum-based chemotherapy prognosis in lung cancer patients.

Materials and methods
=====================

Subjects
--------

351 lung cancer patients were recruited in the study between November 2011 and May 2013 in Xiangya Hospital of Central South University and Hunan Provincial Tumour Hospital in Changsha, Hunan Province, and clinical data were collected in the same place. No patients had received surgery, targeted therapy, radiotherapy, and/or biological therapy before first-line chemotherapy. In demographic characteristics study and outcome analysis, we excluded 3 patients who had incomplete clinical information. In tumor progression analysis, we excluded 46 patients who had incomplete TNM stage information. All subjects were Han people of Chinese and successfully genotyped after donated 5 mL blood, all patients were treated with platinum-based therapy, and each had signed informed consent. A standard follow-up was carried out to collect characteristic data. Clinical data including age, gender, smoking history, family history of cancer, histology classification, TNM stage, and Eastern Cooperative Oncology Group Performance Status. The last follow-up date was in July 2019.

SNPs selection and genotyping
-----------------------------

*HMGB1* SNPs (rs1045411, rs1412125, and rs2249825), *REV3L* SNPs (rs462779 and rs465646), and *NFE2L2* SNPs (rs6706649, rs6721961, and rs35652124) were selected for genotyping in the Han Chinese patients. They were chosen according to the following criteria: (1) based on our previous research, *HMGB1* SNPs were related with lung cancer platinum-based chemotherapy response [@B18], (2) association with the outcome of cancers and involvement in other cancer types in other research, (3) functional relevance of gene transcription or protein expression.

EDTA tube was used to hold 5 mL of venous blood donated from each patient. DNeasy Blood & Tissue Kit (Qiagen, Shanghai, China) or Genomic DNA Purification Kit (Promega, Madison, WI, USA) was used to extracting genomic DNA based on the instructions. Sequenom Mass Array Genotype Platform (Sequenom, San Diego, CA, USA) was used to genotype SNPs of each gene. Primers were designed using Primer-Premier 6 software (Premier Biosoft Interpairs, Palo Alto, CA). The Sequenom Mass Array Genotype Platform was used to design polymerase chain reaction (PCR), the shrimp alkaline phosphatase enzyme (SAP) reaction and associated extension reactions. The PCR system was heating for 15 minutes at 94℃, thermocycling for 45 times (94℃ for 20 seconds, 56℃ for 30 seconds, then 72℃ for 1 minute) and extension at 72℃ for 3 minutes. The SAP reaction was performed at 37℃ for 40 minutes then 85℃ for 5 minutes. The extension reaction was conducted at 94℃ for 30 seconds, 94℃ for 5 seconds, 40 cycles for 5 seconds at 52℃, five cycles for 5 seconds at 80℃, finally 72℃ for 3 minutes. The resin was used to purify the reaction product, and the Mass Array system (Sequenom) was used to resolve the data.

Statistical analysis
--------------------

The SPSS version 25.0 (SPSS Inc., Chicago, IL, USA) and GraphPad Prism (version 8, GraphPad Software Inc., San Diego, CA) were used for statistical analysis. Three genetic models (additive, dominant, and recessive model) were applied to evaluate the association between SNPs and prognosis of lung cancer patients. Overall survival (OS) and progression-free survival (PFS) were analyzed as endpoints and were defined as the time from diagnosis to death for any reason, the time from diagnosis to the first time when patients progressed, respectively. The association between clinical or SNPs data and OS or PFS was assessed using Cox proportional hazards regression analysis, computed as HRs with corresponding 95% CIs. Binary logistic regression was used to test the difference in disease progression between groups. The log-rank test was used to examine the difference in overall survival or progression-free survival between groups. Kaplan-Meier plot was used to visualize the results. All the *P*-values were two-sided, *P*\<0.05 were supposed to be significant.

Results
=======

Demographic characteristics of patients and prognosis analysis
--------------------------------------------------------------

A total of 348 subjects were included in this investigation, all had received platinum-based chemotherapy. As shown in Table [1](#T1){ref-type="table"}, the median age was 56 years (a range of 21 to 75 years). Among them, 78 (22.4%) were females, 270 (77.6%) were males. There were 205 (58.9%) patients who had ever smoked, and the rest 143 (41.1%) patients never smoked. Most of the patients (95.4%) did not have a family history of cancer. For histology, 179 (51.4%) patients were diagnosed with adenocarcinoma, 142 (40.8%) with squamous cell carcinoma, the remainings with other types. 338 (97.1%) of the patients were in an advanced stage (stage III or IV). Likewise, most patients (94.0%) were with Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1. In the univariate Cox regression analysis, histology was significantly associated with progression-free survival, the risk of progression in patients with squamous cell carcinoma (HR=0.69, 95% CI=0.54-0.89, *P*=0.004) was lower than that in patients with adenocarcinoma**(Table [1](#T1){ref-type="table"})**.

Relationship between the eight SNPs and clinical outcome of platinum-based chemotherapy
---------------------------------------------------------------------------------------

Log-rank test and multivariate Cox regression analysis with adjustment for age, gender, and histology were conducted to analyze the association between the eight SNPs and OS or PFS. The rs462779 in *REV3L* was significantly correlated with overall survival of lung cancer patients in the additive (*P* for log-rank=0.018) and recessive (*P* for log-rank=0.005) models (**Table [2](#T2){ref-type="table"}**). Patients carrying TC or CC genotype in rs462779 showed a markedly lower death risk (HR=0.67, 95% CI=0.51-0.90, *P*=0.007) when compared with TT genotype in the recessive model**(Table [2](#T2){ref-type="table"})**. There was also a trend difference in progression risk that patients with TC or CC genotype had better progression-free survival (*P* for log-rank=0.034), while the *P*-value for Cox regression (HR=0.77, 95% CI=0.59-1.02, *P*=0.073) was not significant (**Table [2](#T2){ref-type="table"}**). Additionally, patients carrying AG or GG genotype in rs1045411 were significantly related to better overall survival (HR=0.61, 95% CI=0.38-0.99, *P*=0.046) **(Table [2](#T2){ref-type="table"})**. The other SNPs were not significantly associated with either OS or PFS.

Association between the eight SNPs and lung cancer progression
--------------------------------------------------------------

To investigate whether the eight single nucleotide polymorphisms were related to tumor progression, binary logistic regression was used to analyze the association. As shown in Table [3](#T3){ref-type="table"}, patients carrying *REV3L* rs462779 TC or TT genotypes had a lower hazard (OR=0.38, 95% CI=0.17-0.89, *P*=0.025) of lymph node metastasis in the dominant model when compared with patients carrying CC genotype. The rs1045411 and rs2249825 in *HMGB1* gene were significantly associated with T stage. Patients with AG or AA genotype in rs1045411 were significantly related to early T stage (T1 or T2) when compared with GG genotype (OR=0.47, 95% CI=0.29-0.76, *P*=0.002), and patients with GC or GG genotype in rs2249825 were also associated with early T stage when compared with CC genotype (OR=0.56, 95% CI=0.33-0.94, *P*=0.028) **(Table [3](#T3){ref-type="table"})**.

Subgroup analysis of association between *REV3L*/*HMGB1* polymorphisms and prognosis
------------------------------------------------------------------------------------

To further study the associations of rs462779 and rs1045411 with the prognosis of platinum-based chemotherapy, multivariate Cox proportional hazard analysis was performed in the recessive model stratified by clinical characteristics. In the patients with younger age (≤56 years old), we observed that the TC or CC genotype in rs462779 had significantly lower death risk (HR=0.61, 95% CI=0.42-0.91, *P*=0.015) when compared with TT genotype. For male patients, the TC or CC genotype also had significantly lower death risk (HR=0.69, 95% CI=0.50-0.96, *P*=0.027). For patients who had ever smoked, carrying TC or CC genotype had significantly lower death risk (HR=0.65, 95% CI=0.45-0.95, *P*=0.026). For patients without a family history of cancer, the HR for death of carrying TC or CC genotype was 0.68 (95% CI=0.51-0.92, *P*=0.011). In adenocarcinoma subgroup, the hazard ratio for death was 0.65 (95% CI=0.45-0.94, *P*=0.023). Those with advanced stage (stage III or IV) carrying TC or CC genotype had lower death risk (HR=0.68, 95% CI=0.51-0.91, *P*=0.009). For those who had Eastern Cooperative Oncology Group Performance Status 0 or 1 score, the HR for death of carrying TC or CC genotype was 0.67 (95% CI=0.49-0.90, *P*=0.008)**([Supplementary Table 1](#SM0){ref-type="supplementary-material"}, Figure [1](#F1){ref-type="fig"}A-[1](#F1){ref-type="fig"}G)**.

For *HMGB1* rs1045411, patients with advanced stage (stage III or IV) carrying AG or GG genotype had lower death risk (HR=0.62, 95% CI=0.38-1.00, *P*=0.050) when compared with AA genotype. For patients with ECOG PS 0 or 1 score, the hazard ratio for death of carrying AG or GG genotype was 0.57 (95% CI=0.35-0.93, *P*=0.025)**([Supplementary Table 2](#SM0){ref-type="supplementary-material"}, Figure [1](#F1){ref-type="fig"}H and [1](#F1){ref-type="fig"}I)**.

Discussion
==========

Platinum remains the commonly used drug for lung cancer patients, it is generally used in combination with other antitumor drugs, but the appearance of drug resistance leads to unsatisfied efficacy. Stable DNA adducts formed by cisplatin lead to DNA damage then mainly pursuit to nucleotide excision repair, finally result in cell apoptosis [@B6], [@B7]. Enhanced DNA repair contributes to platinum resistance, which compromises the chemotherapy efficacy and therefore influences clinical outcome [@B10].

Polymorphism is one of the factors that may affect prognosis, and variants of genes of drug transporters, metabolic enzymes, DNA repair system, apoptosis pathway, and folate metabolism pathway are the most studied biomarkers for predicting platinum-based chemotherapy response, while more meaningful markers still need to be discovered [@B10].

In the present study, we focused on the genetic alterations of *HMGB1*, *REV3L*, and *NFE2L2*, a total of eight SNPs, to study the prognostic effect of platinum-based chemotherapy. Among them, *REV3L* rs462779 and *HMGB1* rs1045411 were significantly associated with overall survival; none of them was significantly associated with progression-free survival. In male patients, patients who never smoked, or patients with younger age (≤56), no family history of cancer, adenocarcinoma, advanced tumor (stage III or IV), or ECOG PS 0-1, patients carrying TC or CC genotype in rs462779 had better overall survival when compared with TT genotype. Patients carrying AG or GG genotype in rs1045411 had better overall survival in lung cancer patients with advanced stage (stage III or IV) or ECOG PS 0-1. In terms of tumor progression, carrying TC or TT genotype in *REV3L* rs462779 had a lower risk of lymph node metastasis when compared with CC genotype, while carrying AG or AA genotype in *HMGB1* rs1045411 or carrying GC or GG genotype in *HMGB1* rs2249825 were significantly related to early T stage (T1 or T2).

*REV3L* is an important DNA polymerase involved in DNA replication, repair, recombination, and has an increased mRNA expression in non-small cell lung cancer tissue, the C-terminal portion encompasses conserved DNA polymerase domain, and the N-terminal domain contains residues direct contacting to DNA [@B20], [@B31]-[@B33]. Pol zeta plays a major extender role in translesion DNA synthesis (TLS) after DNA lesions due to its capability to extend mismatched or distorted primer templates of sorts, the lesions were directly bypassed by specialized DNA polymerases, such as DNA polymerases zeta [@B34], [@B35]. Loss expression of *REV3L* increases the frequency of chromosome translocation and break, thus results in genomic instability, and it acts on as a tumor suppressor because of inhibition of spontaneous tumor formation [@B31], [@B35], [@B36]. *REV3L* rs462779 is a nonsynonymous SNP (p.Thr1224Ile) that may influence protein function, *REV3L* rs465646 alters the microRNA binding site in the 3´-UTR, thus may affect *REV3L* expression [@B24].

Genetic variations in *REV3L* have been reported that it was associated with tumor risk or survival in multiple kinds of tumors. Patients carrying the TC or TT genotype in rs462779 had significantly increased colorectal cancer risk, and *REV3L* rs462779 and *RAD18* rs373572 seemed to have a strong cumulative relation with CRC risk, while carrying the TC or CC genotype in rs465646 had significantly decreased lung cancer risk [@B25], [@B37]. Carrying the TC or CC genotype in rs462779 or carrying the AG or GG genotype in rs465646 was associated with good overall survival in platinum-treated malignant mesothelioma patients (n=139), the TC or CC genotype in rs462779 had poor overall survival in osteosarcoma patients (n=66), the TC or CC genotype in rs462779 had poor event-free survival in aggressive breast cancer patients (n=738) [@B24], [@B38], [@B39].

Furthermore, *REV3L* rs462779 showed a slight association with severe toxicity (thrombocytopenia) in NSCLC patients treated with platinum-based chemotherapy [@B40]. Nonetheless, there is no report about the association between OS or PFS and polymorphisms in the platinum resistance-related *REV3L* gene. In our research, carrying TC or CC genotype in rs462779 had good overall survival in lung cancer patients (n=348), but no SNP was significantly associated with progression-free survival. It perhaps due to the differences in sample size and tumor type compared with previous studies. Besides, patients carrying TC or TT genotype had a lower risk of lymph node metastasis. However, the mechanisms of how rs462779 influences overall survival and lymph node metastasis still need further investigation.

*HMGB1* plays nuclear factor role or extracellular signaling molecule role during cell migration and tumor metastasis. Overexpression of *HMGB1* induced by chemotherapy or radiotherapy was associated with all hallmarks of cancer, which leads to tumor microenvironment disorder [@B12], [@B13], [@B41]. Recent studies also show that *HMGB1* is involved in positive regulation and maintenance of ferroptosis in acute myeloid leukemia (AML) cells and autophagy in thyroid cancer cells, also prevents necroptosis in AML cells [@B42]-[@B44]. On the aspect of cancer risk, rs1045411 was significantly associated with susceptibility to hepatocellular carcinoma, oral squamous cell carcinoma, lung cancer, breast cancer, and urothelial cell carcinoma [@B15]-[@B17], [@B45], [@B46]. In terms of association of genetic variants of *HMGB1* and prognosis, previous reports showed that carrying AG or AA genotype of rs1045411 in *HMGB1* gene was significantly associated with good overall survival in gastric cancer patients [@B14]. *HMGB1* rs1045411 is located in the 3\'UTR, and was reported to decrease *HMGB1* expression through *hsa-miR-505-5p* [@B45], [@B47]. *HMGB1* rs1045411 C/T heterozygous polymorphism was associated with a significantly lower ratio of developing EGFR mutation in the smoking population; it may be a protective factor in lung adenocarcinoma [@B47]. In our study, carrying AG or GG genotype in rs1045411 was significantly associated with good overall survival. Moreover, rs1045411 and rs2249825 were significantly related to the early T stage.

There are also some limitations in our study. The recruitment hospitals are located in the same region, and the multi-central clinical studies may be needed to overcome results bias. It is a retrospective study with the sample size not large enough, therefore prospective or other analogous studies are warranted to validate our results. Thus we are enrolling other patients and independent validation will be done in our next studies. The underlying mechanism of rs462779 relating with cancer prognosis still needs further investigation.

In conclusion, our study suggested that *REV3L* rs462779 was significantly associated with overall survival and lymph node metastasis in lung cancer patients with platinum-based chemotherapy, and *HMGB1* rs1045411 was related to overall survival and T stage. Genotypes of *REV3L* rs462779 and *HMGB1* rs1045411 may be biomarkers for predicting platinum-based chemotherapy prognosis in lung cancer patients.
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![**Kaplan-Meier plots of stratified analysis of lung cancer patients with rs462779 (A-G) or rs1045411 (H-I) in recessive model. A,** Overall survival of patients with age ≤56 years old. **B,** Overall survival of male lung cancer patients. **C,** Overall survival of lung cancer patients who had never smoked. **D,** Overall survival of lung cancer patients without a family history of cancer. **E,** Overall survival of lung cancer patients with adenocarcinoma. **F,** Overall survival of lung cancer patients with an advanced tumor (stage III or IV). **G,** Overall survival of lung cancer patients with Eastern Cooperative Oncology Group Performance Status 0 or 1. **H,** Overall survival of lung cancer patients with an advanced tumor (stage III or IV). **I,** Overall survival of lung cancer patients with Eastern Cooperative Oncology Group Performance Status 0 or 1.](jcav11p4343g001){#F1}

###### 

Distribution of characteristics in lung cancer patients and prognosis analysis (n=348)

  Variables                                               Overall survival (OS)   Progression-free survival (PFS)                                                                                      
  ------------------------------------------------------- ----------------------- --------------------------------- ------- ------------------ ------- ------ --------- ----------- ------------------ -----------
  Age (year)                                                                                                                                                                                           
  ≤56                                                     59.0                    123/171                           0.968   Ref.                       33.2   139/171   0.078       Ref.               
  \>56                                                    60.1                    131/177                                   1.00 (0.78-1.27)   0.968   50.3   137/177               0.81 (0.64-1.03)   0.079
  Gender                                                                                                                                                                                               
  Female                                                  56.7                    55/78                             0.971   Ref.                       35.5   61/78     0.890       Ref.               
  Male                                                    60.5                    199/270                                   1.01 (0.75-1.36)   0.971   42.4   215/270               0.98 (0.74-1.30)   0.890
  Smoking status                                                                                                                                                                                       
  Never smoker                                            60.1                    101/143                           0.401   Ref.                       35.1   114/143   0.541       Ref.               
  Ever smoker                                             59.0                    153/205                                   1.11 (0.87-1.43)   0.401   46.1   162/205               0.93 (0.73-1.18)   0.541
  Family history of cancer                                                                                                                                                                             
  No                                                      59.1                    242/332                           0.646   Ref.                       39.1   263/332   0.808       Ref.               
  Yes                                                     52.9                    12/16                                     1.15 (0.64-2.05)   0.646   38.6   13/16                 1.07 (0.61-1.87)   0.808
  Histology                                                                                                                                                                                            
  LUAD                                                    56.1                    137/179                           0.172   Ref.                       29.0   150/179   **0.014**   Ref.               
  LUSC                                                    63.1                    98/142                                    0.78 (0.60-1.01)   0.062   56.5   104/142               0.69 (0.54-0.89)   **0.004**
  Others^a^                                               60.5                    19/27                                     0.92 (0.57-1.49)   0.740   31.3   22/27                 0.94 (0.60-1.46)   0.767
  TNM stage                                                                                                                                                                                            
  Ⅰ/Ⅱ                                                     66.8                    7/10                              0.606   Ref.                       54.3   8/10      0.729       Ref.               
  III/IV                                                  58.8                    247/338                                   1.22 (0.57-2.58)   0.607   36.8   268/338               1.13 (0.56-2.29)   0.729
  Eastern Cooperative Oncology Group Performance Status                                                                                                                                                
  0-1                                                     59.6                    236/327                           0.362   Ref.                       41.4   258/327   0.516       Ref.               
  \>1                                                     48.6                    18/21                                     1.25 (0.77-2.02)   0.363   22.2   18/21                 1.17 (0.73-1.89)   0.517

MST, median survival time; mo, month; HR, hazard ratio; CI, confidence interval; P1, *P*-value for log-rank test; P2, *P*-value for univariate Cox hazards regression analysis; Ref., reference; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma. *P* \< 0.05 are indicated in bold text.

^a^Other carcinomas include adenosquamous carcinoma, large cell carcinoma, bronchogenic lung cancer, and mucoepidermoid carcinoma.

###### 

Association between single nucleotide polymorphisms (SNPs) and platinum-based chemotherapy prognosis (n=348)

  Gene/SNP     Model       Genotype   Overall survival (OS)   Progression-free survival (PFS)                                                                                              
  ------------ ----------- ---------- ----------------------- --------------------------------- ----------- ------------------ ----------- --------- ------ ----------- ------------------ -------
  HMGB1                                                                                                                                                                                    
  rs1045411    Additive    GG         161/221                 59.1                              0.127       Ref.                           174/221   41.4   0.698       Ref.               
                           AG         75/109                  60.0                                          0.97 (0.74-1.28)   0.850       84/109    35.1               1.04 (0.80-1.35)   0.788
                           AA         18/18                   57.5                                          1.62 (0.99-2.65)   0.054       18/18     54.1               1.21 (0.74-1.97)   0.444
               Dominant    GG         161/221                 59.1                              0.796       Ref.                           174/221   41.4   0.687       Ref.               
                           AG/AA      93/127                  60.0                                          1.06 (0.82-1.37)   0.677       102/127   35.8               1.06 (0.83-1.36)   0.621
               Recessive   AA         18/18                   57.5                              **0.045**   Ref.                           18/18     54.1   0.404       Ref.               
                           AG/GG      236/330                 59.1                                          0.61 (0.38-0.99)   **0.046**   258/330   36.8               0.84 (0.52-1.35)   0.464
  rs1412125    Additive    TT         133/182                 58.1                              0.998       Ref.                           145/182   36.6   0.495       Ref.               
                           CT         104/143                 59.1                                          0.99 (0.76-1.28)   0.910       114/143   42.3               1.01 (0.79-1.29)   0.947
                           CC         17/23                   62.1                                          1.00 (0.60-1.67)   0.990       17/23     62.1               0.76 (0.46-1.26)   0.293
               Dominant    TT         133/182                 58.1                              0.950       Ref.                           145/182   36.6   0.812       Ref.               
                           CT/CC      121/166                 60.4                                          0.99 (0.77-1.27)   0.922       131/166   45.6               0.97 (0.76-1.23)   0.788
               Recessive   CC         17/23                   62.1                              0.991       Ref.                           17/23     62.1   0.238       Ref.               
                           CT/TT      237/325                 58.5                                          0.99 (0.61-1.62)   0.969       259/325   36.6               1.32 (0.80-2.15)   0.275
  rs2249825    Additive    CC         193/264                 58.4                              0.599       Ref.                           211/264   36.6   0.476       Ref.               
                           GC         53/76                   61.1                                          0.95 (0.70-1.29)   0.731       57/76     51.2               0.84 (0.62-1.13)   0.246
                           GG         8/8                     64.1                                          1.38 (0.68-2.80)   0.377       8/8       60.8               1.12 (0.55-2.27)   0.762
               Dominant    CC         193/264                 58.4                              0.820       Ref.                           211/264   36.6   0.297       Ref.               
                           GC/GG      61/84                   61.3                                          0.99 (0.74-1.33)   0.942       65/84     54.1               0.87 (0.66-1.15)   0.317
               Recessive   GG         8/8                     64.1                              0.375       Ref.                           8/8       60.8   0.750       Ref.               
                           GC/CC      246/340                 59.0                                          0.72 (0.35-1.46)   0.359       268/340   39.1               0.86 (0.43-1.75)   0.686
  REV3L                                                                                                                                                                                    
  rs462779     Additive    CC         63/90                   61.4                              **0.018**   Ref.                           68/90     52.6   0.106       Ref.               
                           TC         127/185                 60.1                                          0.94 (0.69-1.27)   0.671       141/185   36.6               1.01 (0.75-1.35)   0.949
                           TT         64/73                   50.3                                          1.42 (1.00-2.02)   **0.050**   67/73     27.8               1.30 (0.93-1.83)   0.131
               Dominant    CC         63/90                   61.4                              0.672       Ref.                           68/90     52.6   0.481       Ref.               
                           TC/TT      191/258                 56.0                                          1.06 (0.79-1.41)   0.706       208/258   36.0               1.09 (0.83-1.43)   0.546
               Recessive   TT         64/73                   50.3                              **0.005**   Ref.                           67/73     27.8   **0.034**   Ref.               
                           TC/CC      190/275                 60.5                                          0.67 (0.51-0.90)   **0.007**   209/275   42.3               0.77 (0.59-1.02)   0.073
  rs465646     Additive    AA         164/219                 60.0                              0.423       Ref.                           179/219   33.2   0.252       Ref.               
                           GA         84/122                  59.0                                          0.91 (0.69-1.18)   0.469       91/122    54.5               0.85 (0.66-1.10)   0.222
                           GG         6/7                     60.3                                          1.37 (0.60-3.12)   0.451       6/7       45.6               1.06 (0.47-2.41)   0.888
               Dominant    AA         164/219                 60.0                              0.393       Ref.                           179/219   33.2   0.125       Ref.               
                           GA/GG      90/129                  59.1                                          0.93 (0.72-1.20)   0.572       97/129    54.0               0.86 (0.67-1.11)   0.250
               Recessive   GG         6/7                     60.3                              0.401       Ref.                           6/7       45.6   0.719       Ref.               
                           GA/AA      248/341                 59.1                                          0.70 (0.31-1.60)   0.401       270/341   39.1               0.89 (0.40-2.02)   0.786
  NFE2L2                                                                                                                                                                                   
  rs6706649    Additive    CC         224/304                 59.1                              0.900       Ref.                           243/304   41.1   0.873       Ref.               
                           CT         29/43                   61.1                                          0.91 (0.62-1.35)   0.642       32/43     34.9               0.91 (0.63-1.33)   0.635
                           TT         1/1                     64.0                                          1.01 (0.14-7.29)   0.992       1/1       64.0               0.78 (0.11-5.64)   0.808
               Dominant    CC         224/304                 64.0                              0.860       Ref.                           243/304   64.0   0.909       Ref.               
                           CT/TT      30/44                   59.1                                          0.98 (0.14-7.04)   0.981       33/44     39.1               1.26 (0.18-9.06)   0.820
               Recessive   TT         1/1                     64.0                              0.860       Ref.                           1/1       64.0   0.909       Ref.               
                           CT/CC      253/347                 59.1                                          0.98 (0.14-7.04)   0.981       275/347   39.1               1.26 (0.18-9.06)   0.820
  rs6721961    Additive    GG         126/176                 59.8                              0.547       Ref.                           138/176   41.4   0.811       Ref.               
                           TG         101/140                 58.5                                          1.08 (0.83-1.41)   0.552       112/140   35.1               1.11 (0.87-1.43)   0.399
                           TT         27/32                   60.1                                          1.27 (0.84-1.94)   0.258       26/32     45.3               1.03 (0.68-1.57)   0.891
               Dominant    GG         126/176                 59.8                              0.466       Ref.                           138/176   41.4   0.567       Ref.               
                           TG/TT      128/172                 58.5                                          1.12 (0.87-1.44)   0.378       138/172   35.8               1.10 (0.86-1.39)   0.444
               Recessive   TT         27/32                   60.1                              0.311       Ref.                           26/32     45.3   0.926       Ref.               
                           TG/GG      227/316                 59.0                                          0.81 (0.55-1.22)   0.315       250/316   36.8               1.02 (0.68-1.53)   0.927
  rs35652124   Additive    TT         71/99                   60.5                              0.951       Ref.                           74/99     39.0   0.675       Ref.               
                           CT         124/165                 58.5                                          1.06 (0.79-1.43)   0.679       137/165   39.1               1.17 (0.88-1.55)   0.289
                           CC         59/84                   58.4                                          1.02 (0.72-1.44)   0.917       65/84     40.1               1.07 (0.77-1.50)   0.693
               Dominant    TT         71/99                   60.5                              0.799       Ref.                           74/99     39.0   0.460       Ref.               
                           CT/CC      183/249                 58.5                                          1.05 (0.80-1.38)   0.735       202/249   39.1               1.13 (0.87-1.48)   0.360
               Recessive   CC         59/84                   58.4                              0.931       Ref.                           65/84     40.1   0.848       Ref.               
                           CT/TT      195/264                 60.3                                          1.02 (0.76-1.37)   0.892       211/264   39.1               1.03 (0.78-1.36)   0.835

MST, median survival time; HR, hazard ratio; CI, confidence interval; P1, *P*-value for log-rank test; P2, *P*-value for multivariate Cox hazards regression with adjustment for age, gender, and histology. *P* ≤ 0.05 are indicated in bold text.

Additive model: comparison between minor allele subjects and major allele subjects.

Dominant model: comparison between minor allele carriers and major homozygous subjects.

Recessive model: comparison between major allele carriers and minor homozygous subjects.

###### 

Association between single nucleotide polymorphisms (SNPs) and lung cancer progression (n=305)

  Gene/SNP     Genotype   T stage   N stage   M stage                                                                                                
  ------------ ---------- --------- --------- ------------------ ----------- ---- ----- ------------------ ----------- ---- ----- ------------------ -------
  HMGB1                                                                                                                                              
  rs1045411    GG         59        130       Ref.                           39   150   Ref.                           51   138   Ref.               
               AG/AA      57        59        0.47 (0.29-0.76)   **0.002**   16   100   1.63 (0.86-3.07)   0.134       37   79    0.79 (0.48-1.31)   0.358
  rs1412125    TT         58        100       Ref.                           35   123   Ref.                           45   113   Ref.               
               CT/CC      58        89        0.89 (0.56-1.41)   0.622       20   127   1.81 (0.99-3.30)   0.054       43   104   0.96 (0.59-1.58)   0.882
               CC         6         11        Ref.                           2    15    Ref.                           3    14    Ref.               
               CT/TT      110       178       0.88 (0.32-2.45)   0.811       53   235   0.59 (0.13-2.66)   0.494       85   203   0.51 (0.14-1.83)   0.302
  rs2249825    CC         79        150       Ref.                           45   184   Ref.                           65   164   Ref.               
               GC/GG      37        39        0.56 (0.33-0.94)   **0.028**   10   66    1.61 (0.77-3.39)   0.205       23   53    0.91 (0.52-1.61)   0.754
  REV3L                                                                                                                                              
  rs462779     CC         28        48        Ref.                           7    69    Ref.                           18   58    Ref.               
               TC/TT      88        141       0.94 (0.55-1.60)   0.805       48   181   0.38 (0.17-0.89)   **0.025**   70   159   0.71 (0.39-1.28)   0.252
               TT         30        38        Ref.                           16   52    Ref.                           20   48    Ref.               
               TC/CC      86        151       1.39 (0.80-2.40)   0.242       39   198   1.56 (0.81-3.01)   0.183       68   169   1.04 (0.57-1.87)   0.908
  rs465646     AA         77        118       Ref.                           34   161   Ref.                           50   145   Ref.               
               GA/GG      39        71        1.19 (0.73-1.93)   0.486       21   89    0.90 (0.49-1.64)   0.718       38   72    0.65 (0.39-1.09)   0.100
  NFE2L2                                                                                                                                             
  rs6706649    CC         99        165       Ref.                           46   218   Ref.                           76   188   Ref.               
               CT/TT      17        24        0.85 (0.43-1.65)   0.627       9    32    0.75 (0.34-1.68)   0.484       12   29    0.98 (0.47-2.01)   0.950
  rs6721961    GG         64        88        Ref.                           33   119   Ref.                           44   108   Ref.               
               TG/TT      52        101       1.41 (0.89-2.25)   0.145       22   131   1.65 (0.91-2.99)   0.098       44   109   1.01 (0.62-1.66)   0.971
               TT         13        18        Ref.                           7    24    Ref.                           8    23    Ref.               
               TG/GG      103       171       1.20 (0.56-2.55)   0.637       48   226   1.37 (0.56-3.37)   0.489       80   194   0.84 (0.36-1.97)   0.693
  rs35652124   TT         38        52        Ref.                           19   71    Ref.                           24   66    Ref.               
               CT/CC      78        137       1.28 (0.78-2.12)   0.330       36   179   1.33 (0.72-2.47)   0.367       64   151   0.86 (0.49-1.49)   0.586
               CC         26        41        Ref.                           12   55    Ref.                           24   43    Ref.               
               CT/TT      90        148       1.04 (0.60-1.82)   0.883       43   195   0.99 (0.49-2.01)   0.976       64   174   1.52 (0.85-2.70)   0.156

OR, odds ratio; CI, confidence interval; P, P-value for binary logistic regression analysis; Ref., reference. P \< 0.05 are indicated in bold text.
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